У поліції повідомили про посилене патрулювання в Києві у четверту річницю Революції гідності

21 листопада, у четверту річницю Революції гідності, коли в Україні відзначатимуть День гідності і свободи, поліція посилить патрулювання Києва, повідомив керівник столичної поліції Андрій Крищенко на сторінці у Facebook.

«Наймасовіші заходи заплановані у Києві, тож у столицю прибуде чимало людей із інших областей. Тому наше завдання – зробити усе, аби на належному рівні гарантувати порядок і безпеку громадян.

Складна ситуація на сході держави, резонансні злочини у столиці та області, хвиля неправдивих повідомлень про замінування різноманітних об’єктів, насторожлива оперативна інформація і постійна терористична загроза – усе це спонукає нас до посилення заходів безпеки», – сказав Крищенко.

За його словами, на вулиці столиці додатково вийдуть близько 2 тисяч правоохоронців: як поліцейських, так і військовослужбовців.

«У аеропорту, на залізничному вокзалі та у центральній частині міста, будуть чергувати озброєні патрулі, кінологи та вибухотехніки. Прошу всіх із розумінням ставитися до тимчасових незручностей», – сказав керівник поліції Києва.

У 2014 році в Україні запровадили День гідності і свободи, який відзначають 21 листопада. Саме того дня у 2013 році в Україні почався Євромайдан – після того, як режим тодішнього президента Віктора Януковича вирішив зупинити підготовку до підписання Угоди про асоціацію з ЄС. Протести тривали до лютого 2014 року. Силовики кілька разів намагалися розігнати учасників протестів.

За даними Генпрокуратури, всього під час Євромайдану потерпіли 2,5 тисячі людей, 104 з них загинули – більшість загинули в лютому 2014 року. Згодом загиблих учасників акцій протесту почали називати Небесною сотнею. За даними Міністерства внутрішніх справ, із 18 лютого до 2 березня 2014 року під час виконання службових обов’язків у центрі Києва загинули також 17 силовиків.


Technology Companies, Retailers Send US Stock Indexes Higher

U.S. stocks are higher Monday as technology and industrial companies, banks and retailers all make modest gains. Drugmakers and other health care companies are trading lower. Companies that make opioid pain medications are down sharply after the government released a much higher estimate of the costs of the ongoing addiction crisis.

Keeping score

The Standard & Poor’s 500 index picked up 5 points, or 0.2 percent, to 2,584 as of 2:15 p.m. Eastern time. The Dow Jones industrial average gained 94 points, or 0.4 percent, to 23,452. The Nasdaq composite advanced 7 points, or 0.1 percent, to 6,789. The Russell 2000 index of smaller-company stocks edged up 6 points, or 0.4 percent, to 1,499.

Tech tie-up

Chipmaker Marvell Technology Group said it will buy competitor Cavium for $6 billion in the latest deal in the semiconductor industry. Cavium climbed $7.48, or 9.9 percent, to $83.31 and it is up 22 percent over the last two weeks on reports Marvell would make a bid. Marvell rose $1.02, or 5 percent, to $21.31.

Other technology companies climbed as well. IBM added $2.01, or 1.3 percent, to $150.98 and Applied Materials picked up $1.12, or 2 percent, to $57.61. Cisco Systems gained 55 cents, or 1.5 percent, to $36.45.

Retail rising again

Retailers continued to move higher. They climbed last week following solid quarterly reports from Wal-Mart, Gap and Ross Stores. That’s given investors hope that shoppers are ready to spend more money. Home improvement retailer Home Depot rose $2.68, or 1.6 percent, to $170.42 and clothing company PVH rose $2.90, or 2.2 percent, to $136.02. Sporting goods retailer Hibbett Sports, after a 15-percent surge Friday, added $1.85, or 10.8 percent, to $18.95.

General electric slide

Industrial companies rose, as 3M gained $2.56, or 1.1 percent, to $231.92 and Boeing added $2.39 to $264.65.

General Electric missed out on those gains as investors continued to wonder about the company’s direction. On Sunday, the Wall Street Journal said that directors with energy and financial backgrounds, as well as GE’s two longest-tenured directors, are likely to leave the board as it shifts its focus away from those industries. The company said earlier this month that it will reduce the number of directors to 12 from the current 18.

GE lost 24 cents, or 1.3 percent, to $17.97.

Drugmaker downturn

A White House group said the opioid drug epidemic cost the U.S. $504 billion in 2016, far larger than other recent estimates, and companies that make those pain medications traded sharply lower.

Last year a separate estimate said the crisis cost the country $78.5 billion in 2013, including lost productivity and health care and criminal justice spending. The Council of Economic Advisers said the new figure reflects the worsening crisis and that earlier figures didn’t calculate deaths or include the use of illegal drugs.

Teva Pharmaceutical Industries fell 77 cents, or 5.6 percent, to $13.07 and Allergan gave up $3.78, or 2.2 percent, to $171.10. Endo International lost 26 cents, or 3.5 percent, to $7.28. Insys Therapeutics shed 20 cents, or 3.6 percent, to $6.18. Executives including Insys’ founder and its former CEO have been charged with offering kickbacks to doctors to get them to prescribe its fentanyl spray Subsys. Its stock traded above $40 in mid-2015.

Merck-y future?

Merck stumbled after Genentech, a unit of Swiss drugmaker Roche, reported positive results from a study of its drug Tecentriq as a primary treatment for lung cancer. Genentech said patients who were given Tecentriq as part of their treatment regimen were less likely to die or see their cancer get worse.

The results could affect sales of Merck’s drug Keytruda and Bristol-Myers Squibb’s Opdivo. Merck fell $1.10, or 2 percent, to $54.10 and Bristol-Myers Squibb lost 66 cents, or 1.1 percent, to $60.63.


Benchmark U.S. crude fell 50 cents to $56.05 a barrel in New York. Brent crude, which is used to price international oils, dropped 67 cents, or 1.1 percent, to $62.05 a barrel in London.


The dollar rose to 112.64 yen from 112.13 yen late Friday. The euro slipped to $1.1737 from $1.1796 after a group of German political parties couldn’t agree to form a government, which might mean new elections are on the way. A weaker euro is good for companies that export a lot of products, and the German DAX was up 0.7 percent while France’s CAC 40 rose 0.5 percent. The FTSE 100 in Britain added 0.2 percent. In Japan, the Nikkei 225 index lost 0.6 percent and South Korea’s Kospi shed 0.3 percent. Hong Kong’s Hang Seng index added 0.2 percent.


Bond prices edged lower. The yield on the 10-year Treasury note rose to 2.37 percent from 2.35 percent.


Gold slumped $21.20, or 1.6 percent, to $1,275.30 an ounce. Silver sank 53 cents, or 3.1 percent, to $16.84 an ounce. Copper gained 3 cents to $3.09 a pound.


Yellen to Leave Fed Board When New Leader Sworn In

Fed Chair Janet Yellen says she will leave the U.S. central bank’s board when her successor is sworn in early next year.

Jerome Powell was chosen by President Donald Trump to head the Federal Reserve when Yellen’s term expires. Powell must be confirmed by the U.S. Senate before he can take office, but analysts say his approach to managing interest rates is similar to Yellen’s. She is credited with managing the economy in ways that boosted recovery from the 2007 recession and cut unemployment in half.

In her resignation letter to Trump, Yellen said she is “gratified that the financial system is much stronger than a decade ago.” She also noted “substantial improvement in the economy since the crisis.”

Yellen is the first woman to lead the Fed, and was a member of its board of governors before taking the leadership role. Her term on the board does not officially expire until 2024, and she could have stayed on if she wished to do so.

Candidate Trump criticized Yellen during his campaign, but praised her work after he became president.

Yellen has served as vice chair of the Fed, president of the Federal Reserve Bank of San Francisco, and head of President Bill Clinton’s Council of Economic Advisers. She has researched and taught economics at the University of California at Berkeley.


US State of Nebraska OKs Keystone Oil Pipeline Route

Regulators in the U.S. state of Nebraska have voted to approve a route for TransCanada Corp’s Keystone XL pipeline – the last major obstacle to complete the oil pipeline that President Donald Trump has supported.

The regulatory body, which by state law could not consider the risk of leaks or potential environmental impacts, voted to approve the project just days after a leak in a separate pipeline – also named “Keystone” – spilled 5,000 barrels of oil in the nearby state of South Dakota.

The 3-2 decision by the Nebraska Public Service Commission is likely to be challenged in court by environmental activists in the nearly decade-long debate surrounding TransCanada’s project linking Canada’s Alberta oil sands to refineries in the United States.

The commission’s vote does not approve TransCanada’s proposed route, but a modified one which could prove more costly and difficult to build. It was not immediately clear whether the corporation would go through with the project as it considers its commercial viability.

In 2015, the Obama administration rejected construction of the pipeline, saying it would detract from America’s global leadership on issues related to climate change.

But the Trump administration overturned the decision in March, saying that the pipeline is safer than other methods used to transport oil, and calling its completion “long overdue.”

The 1,900-kilometer-long pipeline is designed to transport up to 830,000 barrels per day of tar sand oil from Alberta, Canada, to Nebraska, where it would then enter existing pipelines to the Gulf Coast refineries.

The pipeline construction sparked months of protests by Native Americans and activist groups, who say the project could pollute local water supplies.


Bitcoin Hits Record High After Smashing Through $8,000 for First Time

Bitcoin hit a new record high on Monday after smashing through the $8,000 level for the first time over the weekend, marking an almost 50 percent climb in just eight days.

The new high came after leading U.S. payments company Square Inc. said late last week that it had started allowing select customers to buy and sell bitcoins on its Cash app.

Bitcoin traded as high as $8,197.81 on the Luxembourg-based Bitstamp exchange, up over 2 percent on the day and around 48 percent up since dipping to $5,555 on Nov. 12.

An eye-watering eightfold increase in the value of the volatile cryptocurrency since the start of the year has led to multiple warnings that the market is in a bubble, and institutional investors are broadly staying away.

Retail investors, however, as well as some hedge funds and family offices, are piling into the market. The “market cap” of all cryptocurrencies hit an all-time high of over $242 billion on Monday, according to trade website Coinmarketcap.


Roche Win Boosts Case for Adding Chemo to Cancer Immunotherapy

Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier skepticism.

News that Roche’s immune system-boosting drug Tecentriq delayed lung cancer progression when given alongside chemo and its older drug Avastin validates the approach for the first time in a large Phase III clinical trial.

It is a significant milestone for physicians, patients and investors, who are trying to assess the competitive landscape as drugmakers race to develop better ways to fight tumors in previously untreated lung cancer.

Lung cancer is by far the biggest oncology market and first-line treatment provides access to the most patients, opening up potential annual sales forecast by some analysts at $20 billion.

Roche and Merck & Co have led the way in pioneering so-called “chemo-combo” treatment, while AstraZeneca and Bristol-Myers are betting primarily on mixing two immunotherapies. AstraZeneca notably failed to show a similar

benefit in a high-profile clinical trial in July.

Stefan Zimmermann, an oncologist at Lausanne University Hospital in Switzerland, said the Roche data would help scotch concerns that chemo might hamper the new class of immuno-oncology medicines.

“Many experts in the field will be relieved because there has been uncertainty … I think this will really encourage many of us to use this combination upfront,” he told Reuters. “For now, the only positive data that we have is for chemo combination.”

Merck, in fact, already has U.S. approval to add chemo to its immunotherapy drug Keytruda – but this was based on a small trial and the company withdrew a similar European application last month, knocking confidence in its strategy.

Since Keytruda, Bristol’s Opdivo, Roche’s Tecentriq and AstraZeneca’s Imfinzi are all rival inhibitors of biological switches known as PD-1 or PD-L1, the market is “largely a zero-sum game,” according to Bernstein analyst Tim Anderson.

“Roche’s good fortune means there is less to go around for other companies,” he said.

In the case of Merck, the U.S. drugmaker now faces a rival with a different and perhaps superior drug combination. Roche believes adding Avastin in addition to chemo can further help restore anti-cancer immunity.

For AstraZeneca and Bristol, the bar has just been raised for two other key clinical trials sponsored by the drugmakers that are expected to report results in 2018.

Roche itself will present full results on the ability of its new combination to delay the worsening of lung cancer at a European Society for Medical Oncology meeting in Geneva on December 7. Data on whether it also helps patients live longer is expected in the first half of next year.

Overall survival is the gold standard in cancer care but proving a treatment extends the time before disease progresses is an important marker on the way.

“If there is positive progression-free survival then I think it is very, very likely this will also translate into an overall survival benefit over time,” said Zimmermann.

Reporting by Ben Hirschler; Editing by Mark Potter.


Miami Responds to Threat of Rising Seas

Preparing for a century of steadily higher tides is a central challenge for city officials from Boston to Bangkok. The U.S. city of Miami, Florida, and its neighbors are home to nearly 3 million people and billions of dollars of real estate development. VOA’s Steve Baragona has a look at what rising seas mean for one of the most vulnerable cities in the United States.


«Динамо» планує оскаржити у Лозанні технічну поразку за неявку до Маріуполя

Футбольний клуб «Динамо» (Київ) має намір оскаржити у Спортивному арбітражному суді Лозанни технічну поразку за неявку на матчі до Маріуполя, заявив президент клубу Ігор Суркіс.

«Ми будемо працювати в правовому полі. Більше нічого не говоритиму… Незалежний суд має усе розставити на свої місця», – заявив Суркіс в ефірі телеканалу «2+2» ввечері 19 листопада.

14 листопада Апеляційний комітет Федерації футболу України відхилив апеляційну скаргу клубу «Динамо» (Київ) на зарахування технічної поразки за неявку на матчі до Маріуполя.

Таким чином, апеляційний комітет залишив без змін рішення Контрольно-дисциплінарного комітету ФФУ від 11 вересня 2017 року. Тим рішенням зарахували технічні поразки з рахунком 0-3 за неявку команд клубу «Динамо» на матчі чемпіонатів U-19, U-21 та Української прем’єр-ліги, які мали відбутися в Маріуполі 18, 26 і 27 липня. Рішення Апеляційного комітету може бути оскаржене в Спортивному арбітражному суді в Лозанні у Швейцарії не пізніше ніж через 21 день із моменту його отримання, повідомили у ФФУ.

Останніми днями у клубі «Динамо» (Київ) заявляли, що хотіли б переграти ті матчі з клубом «Маріуполь» і вже згодні поїхати до цього міста, але маріупольський клуб відхилив цю пропозицію.

У серпні Федерація футболу України підтвердила, що матчі між командами футбольних клубів «Динамо» і «Маріуполь», домашні для маріупольського клубу, мають відбутися саме в Маріуполі, що розташований недалеко від лінії фронту, як це було раніше і з іншими домашніми матчами маріупольської команди. У ФФУ тоді додали, що проведення попередніх матчів у Маріуполі «вже довело, що українські спецслужби та правоохоронці гідно справляються зі своїми обов’язками».

Після виходу клубу «Маріуполь» (раніше «Іллічівець») у прем’єр-лігу українського футболу київське «Динамо» заявило, що не поїде на матчі до міста Маріуполя з міркувань безпеки – і, всупереч рішенню ФФУ, дійсно не приїхало. У київському клубі відтак заявляли, що будуть готові зіграти цей матч у Маріуполі, але тільки «після нормалізації оперативної обстановки на маріупольському (приморському) напрямку». У разі неявки на матч команді зараховується технічна поразка.

Із такими ж заявами виступав і львівський клуб «Карпати», але він врешті зіграв у Маріуполі. Також до міста вже приїжджали на матчі й інші клуби прем’єр-ліги.


White House: Opioid Crisis Cost US Economy $504 Billion in 2015

Opioid drug abuse, which has ravaged parts of the United States in recent years, cost the economy as much as $504 billion in 2015, White House economists said in a report made public on Sunday.

The White House Council of Economic Advisers (CEA) said the toll from the opioid crisis represented 2.8 percent of gross domestic product that year.

President Donald Trump last month declared the opioid crisis a public health emergency. While Republican lawmakers said that was an important step in fighting opioid abuse, some critics, including Democrats, said the move was meaningless without additional funding.

The report could be used by the Trump White House to urge Republicans in Congress – who historically have opposed increasing government spending – to provide more funding for fighting the opioid crisis by arguing that the economic losses far outweigh the cost of additional government funding.

Using a combination of statistical models, the CEA said the lost economic output stemming from 33,000 opioid-related deaths in 2015 could be between $221 billion and $431 billion, depending on the methodology used.

In addition, the report looked at the cost of non-fatal opioid usage, estimating a total of $72 billion for 2.4 million people with opioid addictions in 2015. Those costs included medical treatment, criminal justice system expenses and the decreased economic productivity of addicts.

The CEA said its estimate was larger than those of some prior studies because it took a broad look at the value of lives lost to overdoses. The CEA also said its methodology incorporated an adjustment to reflect the fact that opioids were underreported on death certificates.

“The crisis has worsened, especially in terms of overdose deaths which have doubled in the past ten years,” the CEA said.

“While previous studies have focused exclusively on prescription opioids, we consider illicit opioids including heroin as well.”

Opioids, primarily prescription painkillers, heroin and fentanyl, are fueling the drug overdoses. More than 100 Americans die daily from related overdoses, according to the U.S. Centers for Disease Control and Prevention.


With Little Movement, NAFTA Talks Said to Run Risk of Stalemate

Talks to update the North American Free Trade Agreement appeared to be in danger of grinding toward a stalemate amid complaints of U.S. negotiators’ inflexibility, people familiar with the process said on Sunday.

The United States, Canada and Mexico are holding the fifth of seven planned rounds of talks to modernize NAFTA, which U.S. President Donald Trump blames for job losses and big trade deficits for his country.

Time is running short to reach a deal before the March 2018 start of Mexico’s presidential elections, and lack of progress in the current round could put the schedule at risk.

“The talks are really not going anywhere,” Jerry Dias, president of Unifor, the largest Canadian private-sector union, told reporters after meeting with Canada’s chief negotiator on Sunday. “As long as the United States is taking the position they are, this is a colossal waste of time,” said Dias, who is advising the government and regularly meets the Canadian team.

Hanging over the negotiations is the very real threat that Trump could make good on a threat to scrap NAFTA.

Canada and Mexico object to a number of demands the U.S. side unveiled during the fourth round last month, including for a five-year sunset clause that would force frequent renegotiation of the trade pact, far more stringent automotive content rules and radical changes to dispute settlement mechanisms.

Calls for greater US flexibility

“Our internal view as of this morning is that if any progress is to be made, the United States needs to show some flexibility and a willingness to do a deal,” said a Canadian source with knowledge of the talks.

“We are seeing no signs of flexibility now,” added the source, who requested anonymity given the sensitivity of the situation. However, a NAFTA country official familiar with the talks said Canada had not yet submitted any counterproposals to the U.S. demands.

Dias said the United States was showing some signs of flexibility over its sunset clause proposal after Mexican officials floated a plan for a “rigorous evaluation” of the trade pact, but without an automatic expiration.

U.S. negotiating objectives that were updated on Friday appeared to accommodate the Mexican proposal, saying the revised NAFTA should “provide a mechanism for ensuring that the Parties assess the benefits of the Agreement on a periodic basis.”

Canada and Mexico are also unhappy about U.S. demands that half the content of North American-built autos come from the United States, coupled with a much higher 85 percent North American content threshold. Officials are due to discuss the issue from Sunday through the end of the fifth round on Tuesday, Flavio Volpe, president of the Canada’s Automotive Parts Manufacturers’ Association, said there was little chance of making substantial progress on autos in Mexico City, as the U.S. demands were still not fully understood.

“I don’t expect a heavy negotiation here,” he said in an interview on the sidelines of the talks.